Jacksonville Center for Clinical Research

Recent papers from Jacksonville Center for Clinical Research

1. Remote Voice Analysis for Monitoring Ambulatory Heart Failure Patients: Results of the DETECT-HF StudyJACC Heart Failure · 2026
2. Design and baseline data of AZURE-LDL, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVDEuropean Heart Journal · 2026
3. Long-Term Safety of a Novel Antianginal Agent in Patients With Severe Chronic Stable AnginaJournal of the American College of Cardiology · 2007
4. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinicsThe alliance studyJournal of the American College of Cardiology · 2004
5. Long-Term Efficacy and Safety of Evolocumab in Patients With HypercholesterolemiaJournal of the American College of Cardiology · 2019
6. Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at ≥56 years of ageHuman Vaccines & Immunotherapeutics · 2024
7. Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)JAMA · 2024
8. An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular DiseaseJournal of the American College of Cardiology · 2024
9. Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 ResultsJournal of the American Heart Association · 2023
10. An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized studyClinical and Translational Science · 2022
11. Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trialsJournal of clinical lipidology · 2022
12. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) LevelsJAMA · 2022
13. Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1Kidney International Reports · 2021
14. MEDI6012: Recombinant Human Lecithin Cholesterol Acyltransferase, High‐Density Lipoprotein, and Low‐Density Lipoprotein Receptor–Mediated Reverse Cholesterol TransportJournal of the American Heart Association · 2021
15. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1New England Journal of Medicine · 2021
16. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future ProspectsVascular Health and Risk Management · 2020
17. A Comparison of Ezetimibe and Evolocumab for Atherogenic Lipid Reduction in Four Patient Populations: A Pooled Efficacy and Safety Analysis of Three Phase 3 StudiesCardiology and Therapy · 2020
18. Effects of Danicamtiv, a Novel Cardiac Myosin Activator, in Heart Failure with Reduced Ejection Fraction: Experimental Data and Clinical Results from a Phase 2a TrialENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2020
19. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery diseaseVascular Medicine · 2019
20. Balloon-Expandable Vascular Covered Stent in the Treatment of Iliac Artery Occlusive Disease: 9-Month Results from the BOLSTER Multicenter StudyJournal of Vascular and Interventional Radiology · 2019